Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus

2020 ◽  
Vol 50 (4) ◽  
pp. 512-523
Author(s):  
Shohei Tsuji ◽  
Yoshihito Uchida ◽  
Hayato Uemura ◽  
Jun‐Ichi Kouyama ◽  
Kayoko Naiki ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Function ◽  
Direct Acting Antiviral ◽  
Antiviral Therapies ◽  
Portosystemic Shunts ◽  
Cirrhotic Patients ◽  
Direct Acting

Sofosbuvir‐based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection

2019 ◽  
Vol 34 (9) ◽  
pp. 1620-1625 ◽  
Author(s):  
Chen‐Hua Liu ◽  
Tung‐Hung Su ◽  
Chun‐Jen Liu ◽  
Chun‐Ming Hong ◽  
Hung‐Chih Yang ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Genotype ◽  
Direct Acting Antiviral ◽  
Antiviral Therapies ◽  
Genotype 2 ◽  
Direct Acting

Changes in liver function and body composition by direct-acting antiviral therapy for hepatitis C virus infection

2017 ◽  
Vol 48 (5) ◽  
pp. 337-344 ◽  
Author(s):  
Ryosuke Sugimoto ◽  
Motoh Iwasa ◽  
Nagisa Hara ◽  
Yasuyuki Tamai ◽  
Kyoko Yoshikawa ◽  
...  
Keyword(s):  
Body Composition ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Liver Function ◽  
Antiviral Therapy ◽  
Hepatitis C Virus Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting

DI-074 Evaluation of the treatment response with the new direct acting antiviral drugs for the treatment of hepatitis C virus infection in cirrhotic patients

2016 ◽  
Vol 23 (Suppl 1) ◽  
pp. A151.1-A151
Author(s):  
MA Parro Martín ◽  
MA Rodríguez Sagrado ◽  
MR Pintor Recuenco ◽  
N Vicente Oliveros ◽  
M Vélez-Díaz-Pallarés ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Treatment Response ◽  
Antiviral Drugs ◽  
Hepatitis C Virus Infection ◽  
Direct Acting Antiviral ◽  
Cirrhotic Patients ◽  
Direct Acting

scholarly journals Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Theodoros Voulgaris ◽  
Vassilios A. Sevastianos
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
All Cause Mortality ◽  
Life Threatening ◽  
Cirrhotic Patients ◽  
Direct Acting ◽  
Related Mortality

Chronic hepatitis C virus infection is associated with significant morbidity and mortality, as a result of progression towards advanced natural course stages including cirrhosis and hepatocellular carcinoma. On the other hand, the SVR following successful therapy is generally associated with resolution of liver disease in patients without cirrhosis. Patients with cirrhosis remain at risk of life-threatening complications despite the fact that hepatic fibrosis may regress and the risk of complications such as hepatic failure and portal hypertension is reduced. Furthermore, recent data suggest that the risk of HCC and all-cause mortality is significantly reduced, but not eliminated, in cirrhotic patients who clear HCV compared to untreated patients and nonsustained virological responders. Data derived from studies have demonstrated a strong link between HCV infection and the atherogenic process. Subsequently HCV seems to represent a strong, independent risk factor for coronary heart disease, carotid atherosclerosis, stroke, and, ultimately, CVD related mortality. The advent of new direct acting antiviral therapy has dramatically increased the sustained virological response rates of hepatitis C infection. In this scenario, the cardiovascular risk has emerged and represents a major concern after the eradication of the virus which may influence the life expectancy and the quality of patients’ life.

Sign in / Sign up

Export Citation Format

Share Document